[Etoricoxib (Arcoxia)]

Rev Med Liege. 2004 May;59(5):345-9.
[Article in French]

Abstract

Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib. Tablets of 60, 90 and 120 mg are available. The recommended dosage of etoricoxib is 60 mg/day for osteoarthritis, 90 mg/day for rheumatoid arthritis and 120 mg/day for acute gouty arthritis. Etoricoxib's efficacy has been widely studied in comparative studies, showing the same efficacy as non-COX-2 selective NSAID, with fewer gastro-intestinal adverse effects.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Arthritis, Gouty / drug therapy*
  • Arthritis, Rheumatoid / drug therapy*
  • Cyclooxygenase 2
  • Etoricoxib
  • Humans
  • Isoenzymes / antagonists & inhibitors
  • Membrane Proteins
  • Osteoarthritis / drug therapy*
  • Prostaglandin-Endoperoxide Synthases
  • Pyridines / administration & dosage
  • Pyridines / adverse effects
  • Pyridines / therapeutic use*
  • Sulfones / administration & dosage
  • Sulfones / adverse effects
  • Sulfones / therapeutic use*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Isoenzymes
  • Membrane Proteins
  • Pyridines
  • Sulfones
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Etoricoxib